Molecular Partners AG, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced results from parallel laboratory studies conducted in collaboration with academic and government partners in Switzerland and the United States.
- In Vitro Studies Show Ensovibep (MP0420) Maintains Full Potency Against the Known Mutations of SARS-CoV-2, Including Those Present in Variants First Identified in Brazil, California, India, and New York, in Addition to the Previously Reported Varia
- Ongoing Phase 2 Pilot Study of Ensovibep in Ambulatory Patients Now Expanding Into Second Cohort
- Two Global Phase 2 and 3 Clinical Studies of Ensovibep on Track for Initiation This Month
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / May 6, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced results from parallel laboratory studies conducted in collaboration with academic and government partners in Switzerland and the United States. The studies assessed the inhibition of new viral variants by leading SARS-CoV-2 anti-infective molecules, including ensovibep and MP0423. New variants are often associated with faster transmissibility and a potential ability to evade the currently available monoclonal antibodies and the immunity induced by some vaccines. On top of the previously reported inhibition of the variants first identified in the UK and South Africa, the new results reported today show that ensovibep continues to retain full potency against the new viral variants of SARS-CoV-2, including the variants first identified in Brazil, California, and New York as well as the key mutations in the Indian variant.
“By designing ensovibep to target the viral spike protein in three different places, we aimed to create a candidate capable of achieving high potency while retaining efficacy as the virus mutated. These new results show that ensovibep remains, as designed, fully potent against the emerging variants of SARS-CoV-2, which have received increasing attention as our understanding of COVID-19 shifts to regarding it as a chronic, evolving global health concern,” said Patrick Amstutz, Ph.D., chief executive officer of Molecular Partners. “These data are encouraging as we and our partners at Novartis prepare to enter two major clinical trials: EMPATHY in ambulatory patients and the NIH-sponsored ACTIV-3 in hospitalized patients. We are hopeful that these data will translate into patient benefits for those who are potentially infected with these same variants.”
The study design and results will be updated on the research preprint service bioRxiv here. This research builds upon prior analysis of the UK and South African strains, where ensovibep demonstrated full activity, and potential superiority compared to monoclonal antibodies currently being investigated as antiviral cocktails.
In the study update, based on two pseudovirion models, new SARS-CoV-2 variants first identified in Brazil P.1 (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F), California B.1.429 (S13I, P26S, W152C, L452R, D614G), New York B.1.526 (L5F, T95I, D253G, E484K, D614G, A701V) as well as emerging variants R.1 (W152L, E484K, D624G, G769V) and A.23.1 (F157L, V367F, Q613H, D614G, P681R) and the individual key mutations of the variants identified in India, B.1.617 and B.1.618, were analyzed for infectivity in the presence of different inhibitors. Ensovibep was shown to strongly neutralize these variants, as well as variants created to harbor multiple individual key point mutations in SARS-CoV-2. While maintaining inhibitory activity, MP0423, the Company’s second COVID-19 candidate, has shown reduced protection against some of the variants. Specifically, mutations in the N-terminal domain were identified to be the key contributors to some reduction of potency. Further analyses in context of the full lineages B.1.617 and B.1.618, first described in India, are ongoing. Full data can be found in the updated bioRxiv publication linked above.
Molecular Partners’ lead anti-COVID-19 therapeutic candidate, ensovibep, has been administered to healthy subjects in the Company’s Phase 1 trial, with initial results showing it to be well-tolerated, with a half-life in the range of 2-3 weeks. Additionally, a single-arm Phase 2 trial with ensovibep in COVID-19 ambulatory patients was initiated in March 2021 at a single center in the Netherlands. The initial Phase 1 results have informed the decision to move forward with the EMPATHY clinical trial program, which is being conducted by our partner Novartis, with Molecular Partners as sponsor. The EMPATHY trial is a global, multi-center Phase 2 and 3 study that will seek to enroll 2,100 patients with COVID-19 in the ambulatory setting, to evaluate the safety and efficacy of ensovibep in preventing worsening symptoms and hospitalizations. In parallel, ensovibep will also be tested in hospitalized COVID-19 patients, in a new sub-trial of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-3) Program Phase 3 clinical trial.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
For further details, please contact:
Investors:
Seth Lewis
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361
Media:
Shai Biran, Ph.D.
shai.biran@molecularpartners.com
Tel: +1 978 254 6286
Thomas Schneckenburger, European IR & Media
thomas.schneckenburger@molecularpartners.com
Tel: +41 79 407 9952
Forward-looking statements
This press release may contain certain forward-looking statements relating to the company and its business. Although the company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
SOURCE: Molecular Partners AG
View source version on accesswire.com:
https://www.accesswire.com/645029/Molecular-Partners-COVID-19-Antiviral-Candidate-Ensovibep-Maintains-Potent-Neutralization-Against-Emerging-Viral-Variants-In-Vitro
